Literature DB >> 21724338

The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress.

David J Allsop1, Melissa M Norberg, Jan Copeland, Shanlin Fu, Alan J Budney.   

Abstract

BACKGROUND: Rates of treatment seeking for cannabis are increasing, and relapse is common. Management of cannabis withdrawal is an important intervention point. No psychometrically sound measure for cannabis withdrawal exists, and as a result treatment developments cannot be optimally targeted. The aim is to develop and test the psychometrics of the Cannabis Withdrawal Scale and use it to explore predictors of cannabis withdrawal.
METHODS: A volunteer sample of 49 dependent cannabis users provided daily scores on the Cannabis Withdrawal Scale during a baseline week and 2 weeks of abstinence.
RESULTS: Internal reliability (Cronbach's alpha=0.91), test-retest stability (average intra-class correlation=0.95) and content validity analysis show that the Cannabis Withdrawal Scale has excellent psychometric properties. Nightmares and/or strange dreams was the most valid item (Wald χ²=105.6, P<0.0001), but caused relatively little associated distress (Wald χ²=25.11, P=0.03). Angry outbursts were considered intense (Wald χ²=73.69, P<0.0001) and caused much associated distress (Wald χ²=45.54, P<0.0001). Trouble getting to sleep was also an intense withdrawal symptom (Wald χ²=42.31, P<0.0001) and caused significant associated distress (Wald χ²=47.76, P<0.0001). Scores on the Severity of Dependence Scale predicted cannabis withdrawal.
CONCLUSIONS: The Cannabis Withdrawal Scale can be used as a diagnostic instrument in clinical and research settings where regular monitoring of withdrawal symptoms is required.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21724338     DOI: 10.1016/j.drugalcdep.2011.06.003

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  81 in total

1.  Diagnostic criteria for cannabis withdrawal syndrome.

Authors:  David A Gorelick; Kenneth H Levin; Marc L Copersino; Stephen J Heishman; Fang Liu; Douglas L Boggs; Deanna L Kelly
Journal:  Drug Alcohol Depend       Date:  2011-12-07       Impact factor: 4.492

2.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

3.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

4.  Rapid elimination of Carboxy-THC in a cohort of chronic cannabis users.

Authors:  John Lewis; Anna Molnar; David Allsop; Jan Copeland; Shanlin Fu
Journal:  Int J Legal Med       Date:  2015-08-02       Impact factor: 2.686

Review 5.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

6.  Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.

Authors:  Erin A McClure; Nathaniel L Baker; Susan C Sonne; Udi E Ghitza; Rachel L Tomko; LaTrice Montgomery; Shanna Babalonis; Garth E Terry; Kevin M Gray
Journal:  Drug Alcohol Depend       Date:  2018-08-25       Impact factor: 4.492

7.  Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study.

Authors:  Brian J Sherman; Aimee L McRae-Clark; Nathaniel L Baker; Susan C Sonne; Therese K Killeen; Kasie Cloud; Kevin M Gray
Journal:  Am J Addict       Date:  2017-02-02

8.  Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.

Authors:  Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran
Journal:  Lancet Psychiatry       Date:  2020-07-28       Impact factor: 27.083

9.  Marijuana withdrawal and aggression among a representative sample of U.S. marijuana users.

Authors:  Philip H Smith; Gregory G Homish; Kenneth E Leonard; R Lorraine Collins
Journal:  Drug Alcohol Depend       Date:  2013-02-04       Impact factor: 4.492

10.  The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence.

Authors:  David J Allsop; Delwyn J Bartlett; Jennifer Johnston; David Helliwell; Adam Winstock; Iain S McGregor; Nicholas Lintzeris
Journal:  J Clin Sleep Med       Date:  2015-10-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.